A retrospective real-world analysis reports that sustained Zepbound (tirzepatide) use in adults over age 55 with obesity is associated with lower healthcare utilization and reduced costs. The study evaluated claims data from Komodo’s Healthcare Map covering more than 330 million individuals and compared treated patients with matched controls. Across follow-up, patients treated with Zepbound had lower hospital admissions and emergency department visits. Estimated cost differences excluding drug costs ranged from about 15% lower at six months to as much as 38% lower by 12 months, with savings reaching and then exceeding the monthly cost of the Medicare GLP-1 Bridge program. The findings arrive as payers and policymakers increasingly scrutinize the budget impact of GLP-1-based therapies in older populations, where adherence and longer-term economics are key. The analysis is observational and focuses on utilization and cost outcomes, not direct comparative effectiveness in clinical endpoints, but it adds new evidence tied to reimbursement-era implementation decisions.